Skip to Content

'
Nathan H Fowler, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

My interest in immunomodulatory agents began during my hematology/oncology fellowship at Georgetown University Hospital, where I helped develop some of the first protocols to use lenalidomide in CLL.  Since joining the faculty at MD Anderson Cancer Center, the goal of my clinical research has been to further develop novel therapeutic regimens utilizing immunomodulatory agents to benefit patients with low grade non-Hodgkins lymphoma.  I serve as the chairman of several phase I and investigator-initiated phase II trials for patients with non-Hodgkins lymphoma which includes leading the largest clinical study to use immunomodulatory drugs for untreated low grade lymphoma.  I have had the opportunity to develop collaborative relationships with basic scientists across multiple departments, and as a member of the phase I team I have experience developing cutting edge translational projects for patients with lymphoma.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: Unit 429
Houston, TX 77030
Room Number: FC6.3064
Phone: 713-792-2860
Fax: 713-794-5656

Education & Training

Degree-Granting Education

2001 University of Texas Medical Branch, Galveston, TX, MD, Medicine
1997 University of Houston, Houston, TX, BS, Biology

Postgraduate Training

7/2006-6/2007 Chief Fellow, Georgetown University, Washington, DC
7/2004-8/2007 Clinical Fellowship, Hematology/Oncology, Georgetown University, Washington, DC
7/2002-6/2004 Clinical Residency, University of Texas Medical Branch, Galveston, TX
7/2001-6/2002 Clinical Internship, University of Texas Medical Branch, Galveston, TX

Board Certifications

8/2008 Medical Oncology
8/2004 American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2007-5/2013

Administrative Appointments/Responsibilities

Co-Director, Clinical and Translational Research Program, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2012-present
Team Lead, Low Grade Lymphoma Research Group, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-present
Team Lead, CNS Lymphoma Research Group, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2009-present

Other Appointments/Responsibilities

Member, National Cancer Institute (NCI), Follicular Lymphoma Sub Committee, Bethesda, MD, 2013-present
Member, Southwest Oncology Group (SWOG), Lymphoma Steering Committee, Houston, TX, 2013-present

Military or Other Governmental Service

Nuclear, Biological and Chemical Defense Specialist, US Army, 1988-1991

Institutional Committee Activities

Member, Clinical Research Committee, 9/2009-present

Honors and Awards

2006-2007 Georgetown Chief Fellow
1996 Natural Science and Mathematics Scholar and Fellow
1995-1996 Order of Omega Greek Honor Society
1994-1996 Dean's List
1991 National Defense Medal, US Army
1991 Overseas Service Ribbon, US Army
1990 Army Achievement Medal, US Army
1990 Valedictorian. Nuclear, Biological, and Chemical Defense School, US Army

Selected Publications

Peer-Reviewed Original Research Articles

1. Cheah CY, Fowler NH, Wang ML. Breakthrough therapies in B-cell non-Hodgkin lymphoma. Ann Oncol. e-Pub 1/2016. PMID: 26802148.
2. Cheah CY, Mistry HE, Konoplev S, Fowler NH. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma. Leuk Lymphoma. e-Pub 1/2016. PMID: 26762971.
3. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 1/2016. PMID: 26802151.
4. Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity. Br J Haematol. e-Pub 12/18/2015. PMID: 26683805.
5. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med 7(314):314ra185, 11/18/2015. PMID: 26582900.
6. Mahale P, Turturro F, Romaguera JE, Fowler N, Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. Leuk Lymphoma. e-Pub 11/16/2015. PMID: 26402559.
7. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 11/2015. e-Pub 8/2015. PMID: 26250576.
8. Reddy JP, Akhtari M, Smith GL, Pinnix C, Osborne EM, Gunther JR, Allen PK, Yehia ZA, Fanale M, Rodriguez MA, Fowler N, Milgrom SA, Wogan CF, Dabaja BS. Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. Clin Lymphoma Myeloma Leuk 15(11):664-670.e2, 11/2015. e-Pub 8/5/2015. PMID: 26321471.
9. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 11/2015. e-Pub 7/27/2015. PMID: 26213141.
10. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 11/2015. e-Pub 8/10/2015. PMID: 26260306.
11. Cheah CY, Milgrom S, Chihara D, Gombos DS, Pinnix CC, Dabaja BS, Fowler NH. Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. Neuro Oncol. e-Pub 10/20/2015. PMID: 26487691.
12. Cheah CY, Fowler NH. Chemotherapy-Free Treatment of Follicular Lymphoma: We Have the Ingredients, Now for Some Recipes. Oncology (Williston Park) 29(10):769, 772, 10/2015. PMID: 26470902.
13. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol. e-Pub 9/11/2015. PMID: 26358140.
14. Gribben JG, Fowler N, Morschhauser F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol 33(25):2803-11, 9/2015. e-Pub 7/2015. PMID: 26195701.
15. Cheah CY, Fowler NH, Neelapu SS. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol 27(5):384-91, 9/2015. PMID: 26248256.
16. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 26(8):1667-77, 8/2015. e-Pub 2/23/2015. PMID: 25712458.
17. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922-6, 8/2015. e-Pub 7/20/2015. PMID: 26193343.
18. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 7/2015. e-Pub 3/27/2015. PMCID: PMC4486240.
19. Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang ML. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26(6):1175-9, 6/2015. e-Pub 2/23/2015. PMID: 25712454.
20. Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 125(21):3357-9, 5/21/2015. PMID: 25999447.
21. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 5/1/2015. PMCID: PMC4418193.
22. Akhtari M, Reddy JP, Pinnix CC, Allen PK, Osborne EM, Gunther JR, Milgrom SA, Smith GL, Wogan CF, Fowler N, Rodriguez MA, Dabaja B. Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. Leuk Lymphoma. e-Pub 5/12/2015. PMID: 25860237.
23. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 5/1/2015. PMCID: PMC4418191.
24. Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol 94(4):633-641, 4/2015. e-Pub 1/30/2015. PMID: 25630297.
25. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/28/2014. PMCID: PMC4344896.
26. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 13(1):41-50, 1/2015. PMID: 25583768.
27. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10(1):206, 2015. e-Pub 9/25/2015. PMCID: PMC4582821.
28. Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 11/2014. e-Pub 10/2014. PMCID: PMC4370362.
29. Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW. (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. Br J Haematol 167(2):207-13, 10/2014. e-Pub 7/2014. PMID: 25040450.
30. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 10/2014. e-Pub 7/2014. PMID: 25039868.
31. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
32. Fowler NH. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma. Clin Adv Hematol Oncol 12(9):608-10, 9/2014. PMID: 25654483.
33. Liao B, Kamiya-Matsuoka C, Gong Y, Chen M, Wolf BA, Fowler NH. Primary natural killer/T-cell lymphoma presenting as leptomeningeal disease. J Neurol Sci 343(1-2):46-50, 8/2014. e-Pub 5/2014. PMID: 24880537.
34. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma 55(5):1013-7, 5/2014. e-Pub 8/2013. PMID: 23879202.
35. Fowler N. Indolent and mantle cell NHL: the future is BRIGHT. Blood 123(19):2905-6, 5/2014. PMID: 24810622.
36. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/2014. PMID: 24386943.
37. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/2013. PMCID: PMC3922714.
38. Kim MM, Dabaja BS, Medeiros J, Kim S, Allen P, Chevez-Barrios P, Gombos DS, Fowler N. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience. Am J Clin Oncol. e-Pub 1/2014. PMID: 24390272.
39. Fowler N. Frontline Management Strategies for Younger, Fit Patients with Mantle Cell Lymphoma. Clinical Advances in Hematology/Oncology 11(12):4-6, 12/2013.
40. Kahl BS, Fowler NH, Czuczman MS. Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol 11(12 Suppl 19):1-15, 12/2013. PMID: 24893155.
41. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/2013. PMID: 24117234.
42. Fowler N. Novel Treatment Approaches to Mantle Cell Lymphoma. Clinical Advances in Hematology/Oncology 11(11):14-18, 11/2013.
43. Rosen ST, Link BK, Fowler NH. Unmet needs in the treatment of mantle cell lymphoma. Clin Adv Hematol Oncol 11(11 Suppl 18):1-19, 11/2013. PMID: 24893041.
44. Oki Y, Buglio D, Fanale MA, Fayad L, Copeland AR, Romaguera J, Kwak LW, Pro B, Faria SD, Neelapu SS, Fowler N, Hagemeister FB, Zhang J, Zhou S, Feng L, Younes A. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. e-Pub 10/2013. PMID: 24097867.
45. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 7/2013. e-Pub 4/2013. PMID: 23590726.
46. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol 190(12):6681-93, 6/2013. e-Pub 5/2013. PMCID: PMC3680117.
47. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell Non-Hodgkin lymphoma. Br J Haematol. e-Pub 6/2013. PMID: 23795711.
48. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah JJ, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 4/2013. e-Pub 4/2013. PMID: 23545991.
49. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/2012. PMID: 23276888.
50. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. J Clin Oncol 31(1):88-94, 1/2013. e-Pub 10/2012. PMID: 23045577.
51. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol Educ Book:366-72, 2013. PMID: 23714549.
52. Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013:553-60, 2013. PMID: 24319231.
53. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. e-Pub 6/2012. PMID: 22677155.
54. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
55. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 6/2012. e-Pub 5/2012. PMID: 22586182.
56. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA, Letzer J, Amin B, Williams ME, Smith S, Saleh A, Rosen P, Shi H, Parasuraman S, Cheson BD. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II VERTICAL study. J Clin Oncol 29(25):3389-95, 9/2011. e-Pub 8/2011. PMID: 21810687.
57. Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy in the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics 36(9):590-598, 9/2011.
58. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma. Clin Nucl Med 36(4):317-9, 4/2011. PMID: 21368613.
59. Mazloom A, Rodriguez A, Ha CS, Medeiros LJ, Wogan C, Shihadeh F, Allen P, Fowler N, Dabaja B. Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma. Cancer. e-Pub 12/2010. PMID: 21157949.
60. Phan J, Mazloom A, Medeiros J, Shihadeh F, Rodriguez A, Fayad L, Fowler N, Reed V, Horace P and Dabaja B. The benefit of consolidative radiation therapy in patients with diffuse large b-cell lymphoma treated with R-CHOP chemotherapy. Journal of Clinical Oncology 28(27)(4):4105-7, 9/2010. PMID: 20713859.
61. Mazloom A, Fowler N, McLaughlin P, Iyengar P, Cabinillas F, Fayad L, Pro B, Medeiros J, Rodriguez A, Reed V, Urbauer D, Gonzalez G, Dabaja B. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma 51(7):1217-1224, 7/2010. PMID: 20443676.
62. Goldman L, Ezzat S, Mokhtar N, Abdel-Hamid A, Fowler N, Gouda I, Eissa S, Abdel-Hamid M, Loffredo C. Viral and non-viral risk factors for non-Hodgkin's Lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 20(6):981-7, 8/2009. e-Pub 3/2009. PMID: 19263231.
63. Fowler N, Younes A. There will be blood: targeting tumor vasculature. Blood 113(10):2121-2122, 3/2009. PMID: 19264922.
64. Fowler N, Asatiani E, Cheson B. Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma. Leuk Lymphoma 49(1):156-8, 1/2008. PMID: 18203026.
65. Fowler N, Spell D. Case report. Parotid gland metastasis as the initial manifestation of a non-small cell lung cancer. Southern Medical J. Vol 95:S:25, 2002.

Abstracts

1. d Vos S, Swinnen L, Kozloff M, Wang, D, Reid E, Nastoupil L. Fowler N, Cordero J, D'Amico D, Dielh S, Dunbar M, Zhu M, Wong S, Enschede SH, Clien D, Humerickhouse RA and Flowers C. A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in patient swith Relapsed or Refractory Non-Hodgkin's Lymphoma. Blood 126(23):255, 12/2015.
2. Fowler N, Pinto RM, Cheah CY, Neelapu S, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F and Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Anti-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23):2742, 12/2015.
3. Jain P, Patel KP, Futreal A, Gumbs C, Hu S, Ramos CB, Wang M, Romaguera J, Fayad LE, Orlowski R, Medeiros J and Fowler N. Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS). Blood 23(2700), 126, 12/2015.
4. Fanale, MA, Wang Z, Ma W, Oki Y, Hagemeister, F, Fayad, LE, Fowler, N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto T, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas. Blood 126(23):2705, 12/2015.
5. Chihara D, Oki Y, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horowitz SB, Feng L, Garg N, Ahmed S, Khouri IF, Hosing CM, Romaguera JE, Fowler N and Fanale MA. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood 126(23):3987, 12/2015.
6. Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen R, Advani RH, Bhatia S, Martin P, Mena R, Suzuki S, Beaupre DM, Neuenburg JK and Palomba ML. Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. Blood 23(470), 126, 12/2015.
7. Wang Y, Wagner-Bartak N, Zhou S, Fowler N, Dela Rosa ML, Zhao D, Romaguera JE, Neelapu JS, Hagemeister FB, Fanale MA, Oki Y, Shah J, Thomoas SK, Hosing CM, Zhang L, Badillo M, Chen W, Cai Q, Zou D, Champlin RE, Fayad LE, Lee HJ and Wang M. Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial. Blood 126(23):3969, 12/2015.
8. Fowler N, Boyd TE, Sharman JP, Smith SM, Clow F, Chu AD and Advani RH. Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. Blood 126(23):2706, 12/2015.
9. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu S, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE and Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23):1502, 12/2015.
10. Wang B, Zhang L, Pham L, Tao W, Zhang H, Xie J, Chen W, Cai Q, Zou D, Zhao D, Sun X, Liang R, Wang J, Nomie K, Fowler N and Wang M. The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma. Blood 126(23):5126, 12/2015.
11. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23):2738, 12/2015.
12. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu S, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Yago Nieto Y, Davis RE and Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. Blood 126(23):3984, 12/2015.
13. Lunning MA, Vose J, Fowler N, Nastoupil L, Burger JA, Wierda W, Schreeder MT, Siddiqi T, Flowers C, Cohen JB, Blumel S, Miguel M, Cutter K, Pauli EK, Handy R, Sportelli P, HP M, Weiss MS and O'Brien S. Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. Blood 126(23):1538, 12/2015.
14. Cheah CY, Chihara D, Sevin A, Horowitz S, Oki Y, Fowler N, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Westin J, Romaguera J, Fayad L, Samaniego F and Fanale MA. Patients with Classical Hodgkin Lymphoma Failing Brentuximab Vedotin have Brief Responses to Salvage Therapies and Limited Survival. HAA Annual Scientific Meeting 2015 (#644), 10/2015.
15. Fowler N, Cheah C, Neelapu S, Nastoupil L, Turturro F, Hagemeister F, Kwak L, Romaguera J, Fanale M, Fayad L, Claret L, Feng L, Davis ER and Samaniego F. Extended Dosing Lenalidomide with Intensified Rituximab in Untreated Indolent NHL. 13th International Conference on Malignant Lymphoma (Palazzo di Congressi, Lugano, Switzerland), 6/2015.
16. Leonard J, Gribben J, Trněný M, Scheinberg P, Tobinai K, Fowler N, Kilavuz N, Fustier P and Amoroso B. AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.J Clin Oncol. J Clin Oncol 33(suppl;abstr TPS8603), 2015.
17. Sargent D, Shi Q, De Bedout S, Flowers C, Fowler N, Fu T, Hagenbeek A, Herold M, Hoster E, Huang J, Kimby E, Ladetto M, Morschhauser F, Nielsen T, Takeshita K, Valente N, Vitolo U, Zucca E and Salles G. Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) analysis with individual patient data (IPD) of 3,837 patients (pts). J Clon Oncol 33(suppl; abstr 8504), 2015.
18. Sehn LH, Chua NS, Mayer J, Dueck GS, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Leonard A, Lugtenburg P, Franklin N, Fritsch EW, Fingerle-Rowson G and Cheson B. GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol 33(suppl; abstr LBA8502), 2015.
19. Chihara D, Pro B, Loghavi S, Miranda R, Medeiros LJ, Fanale M, Hagemeister FB, Fayad L, Romaguera J, Samaniego F, Neelapu S, Younes A, Fowler N, Rodriguez MA, Wang M, Kwak L, McLaughlin P and Dang N, Oki Y. Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL). J Clin Oncol J Clin Oncol(suppl; abstr 8538), 2015.
20. De Vos D, Flowers C, Wang D, Swinnen L, Fowler N, Reid E, Cordero J, Gifford M, D'Amico D, Dunbar M, Zhu M, Salem A, Enschede S, Ricker J, Chien D, Humerickhouse R and KozloffInterim M. results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin’s Lymphoma (NHL). J Clin Oncol 33:(suppl; abstr 8535), 2015.
21. Fowler N, Nastoupil L, Lunning MA, Vose J, Siddiqi T, Flowers C, Cohen JB, Schreeder MT, Miguel M, Blumel S, Phye B, Tse W, Pauli E, Cutter K, Sportelli P, Miskin H, Weiss M, Vakkalanka S, Viswanadha S and O'Brien SM. Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies. J Clin Oncol(33):(supp; abstr 8501), 2015.
22. Lunning MA, Vose J, Fowler NH, Nastoupil L, Schreeder M, Siddiqi T, Flowers C, Cohen JB, Blumel S, Miguel M, Tse W, Pauli E, Cutter K, Sportelli P, Miskin H, Weiss M, Vakkalanka S, Viswanadha S and O'Brien SM. Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL. J Clin Oncol 33(suppl; abstr 8548), 2015.
23. Fanale M, Hagemeister FB, Fayad L, Oki Y, Fowler N, Romaguera J, Shah N, Chuang H, Feng L, Horowitz SB, Wesson E, Hutto TY, Muzzafar T, Samaniego F and Davis RE. 56th ASH Annual Meeting. A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas, 12/2014.
24. Fowler NH. R2-CHOP vs R-CHOP for Diffuse Large B-Cell Lymphoma. Clin Adv Hematol Oncol 12(9):608-10, 9/2014. PMID: 25654483.
25. Nastoupil L, Neelapu S, Samaniego F, Hagemeister FB, Romaguera J, Kwak L, Wang M, Fayad L, Fanale M, Oki Y, Westin J, Rodriguez MA, Cabanillas F, McLaughlin P and Fowler N. 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. J Clin Oncol 32(suppl; abstr 8528):5s, 2014.
26. Fowler N, Hiddemann W, Leonard J, Rose E, Ahmadi T, Vermeulen J, Larsen J, Sun S, Mentzer L, Wang SS, Yeh TM and Salles G. A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. ASCO, 2014.
27. Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez MA, Samaniego F, Fowler N, Oki Y, Turturro F, Westin JR, Kwak L, Dabaja B, Feng L, Davis RE and Neelapu S. Antibiotic Therapy of H. Pylori Negative Gastric MALT Lymphoma. Blood 124:1735, published ahead of print December 5, 2014, 2014.
28. Mahale P, Romaguera J, Turturro F, Fowler N and Torres HA. Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series. Blood 124:5414, published ahed of print December 5, 2014, 2014.
29. de Vos S, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler N, Sharman JP, Boccia RV, Barrientos JC, Rai K, Boyd TE, Furman RR, Holes LM, Kim Y, Godfrey WR and Leonard JP. Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results. Blood 124:3063, published ahead of print December 5, 2014, 2014.
30. Lee SE, Percivalle E, Cheng X, Lizee G, Fowler N, Davis RE and Neelapu S. Intratumoral and Peripheral Blood T Cells Recognize Mutated Neo-Antigens in Follicular Lymphoma. Blood 124:809, published ahead of print December 5, 2014, 2014.
31. Furman RR, de Vos S, Barrientos JC, Schreeder MT, Flinn IW, Sharman JP, Boyd TE, Fowler N, Leonard JP, Rai KR, Kim Y, Viggiano A, Jahn TM and Coutre SE. Long-Term Follow-up of a Phase 1 Study of Idelalisib (ZYDELIG®) in Combination with Anti-CD20 Antibodies (Rituximab [R] or Ofatumumab [O]) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 124:5653, published ahead of print December 5, 2014, 2014.
32. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak L, Neelapu S, Wang M, Feng L and Younes A. Phase II Study of an AKT Inhibitor MK2206 in Patients with Relapsed or Refractory Lymphoma. Blood 124:3093, published ahead of print December 5, 2014, 2014.
33. Gopisetty A, Foglietta M, Zhang M, Wang Z, Fowler N, Davis RE and Neelapu S. Prosurvival and Chemoprotective Effects of Tumor-Associated Macrophages Reversed By Anti-CSF-1R Monoclonal Antibody in B-Cell Lymphomas. Blood 124:498, published ahead of print December 5, 2014, 2014.
34. Phansalka K, Ahmed MA, Fowler N, Ma L, Noorani M, Lee ST, Feng L, Hagemeister FB, Romaguera J, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin J, Nastoupil L, Kwak L, Davis RE and Neelapu S. R-Bendamustine Vs R-CHOP As Initial Treatment for Advanced Stage Low Grade Follicular Lymphoma: A Matched-Pair Analysis. Blood 124:3048, published ahead of print December 5, 2014, 2014.
35. Ahmed MA, Fowler N, Ma L, Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, Oki Y, Turturro F, Westin JR, Kwak L, Nastoupil L, Cheah C, Feng L, Rohren EM, Davis RE and Neelapu S. SUVmax on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Threapy. Blood 124:1629, ; published ahead of print December 5, 2014, 2014.
36. de Vos S, Flowers CR, Wang D, Swinnen LJ, Fowler N, Reid E, Gifford M, D'Amico D, Dunbar M, Zhu M, Yang J, Enschede SH, Ricker JL, Chien D, Humerickhouse RA and Kozloff M. The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma. Blood 124:1722, published ahead of print December 5, 2014, 2014.
37. Mahale P, Turturro F, Romaguera J, Fowler N and Torres HA. The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia. Blood 124:4448, published ahead of print December 5, 2014, 2014.
38. Jain P, Patel K, Bueso-Ramos C, Romaguera J, Fayad L, Kwak L and Fowler N. Treatment of dendritic cell sarcoma: 18-year experience at the MD Anderson Cancer Center. J Clin Oncol 32(suppl;abstr 8596):5s, 2014.
39. Lunning MA, Vose JM, Schreeder MT, Fowler N, Nastoupil L, Siddiqi T, Blumel S, Pauli EK, Cutter K, Tse W, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, Viswanadha S and O'Brien S. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Blood 124:801, published ahead of print December 5, 2014, 2014.
40. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, Kwoh TJ, MacLeod R, Norris D, Baldwin R, Hung G, Monia B, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol ASCO Annual Meeting(8523), 6/2013.
41. Wagner-Johnston N, De Vos S, Leonard J, Porter Sharman J, Schreeder MT, Boccia RV, Barrientos JC, Coutre SE, Flinn I, Boyd TE, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, Fowler NH. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL). J Clin Oncol ASCO Annual Meeting(8501), 6/2013.
42. Leonard J, Wagner-Johnston ND, Coutre SE, Flinn I, Schreeder MT, Fowler NH, Sharman JP, Boccia RV, Barrientos JC, Rai KR, Boyd TE, Furman RR, Holes L, Johnson DM, Kim Y, Dansey RD, Godfrey WR, De Vos S. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): Updated results from a phase I study. J Clin Oncol ASCO Annual Meeting(8500), 6/2013.
43. Barrientos JC, Furman RR, Leonard J, Flinn I, Roop Rai K, De Vos S, Schreeder MT, Wagner-Johnston ND, Porter Sharman J, Boyd TE, Fowler NH, Holes L, Johnson DM, Li D, Dansey RD, Jahn TM, Coutre SE. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL. J Clin Oncol ASCO Annual Meeting(7017), 6/2013.
44. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE, Neelapu SS. Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. J Immunol, 5/2013. PMID: 23686488.
45. Fowler N, Oki Y. Developing novel strategies to target B-cell malignancies. Am Soc Clin Oncol:366-72, 5/2013. PMID: 23714549.
46. Rawal S, Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladadayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte L, Samaniego F, Davis E, and Neelapu S. Activation of T and NK cells following lenalidomide therapy in patients with follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#2766), 11/2012.
47. Fowler N, de Vos S, Schreeder M, Leonard J, Flinn I, Coutre S, Wagner-Johnston N, Sharman J, Boccia R, Barrientos J, Boyd T, Holes L, Lannutti B, Johnson D, Jahn T, Miller L, and Godfrey W. Combinations of the phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor Gs-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-Hodgkin lymphoma: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21) (#3645), 11/2012.
48. Coutre S, Leonard J, Furman R, Barrientos J, de Vos S, Flinn I, Schreeder M, Wagner-Johnston N, Sharman J, boyd T, Fowler N, Holes L, Lannutti B, Johson D, Miller L, and Jahn T. Combinations of the slective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (Cal-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 120(21) (#191), 11/2012.
49. Fowler N, Neelapu S, Hagemeister F, McLaughlin P, Kwak L, Roamguera J, Fnaale M, Fayad L, Orlowski R, Wang M, Turturro F, Oki Y, Lacerte L, and Samaniego F. Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a phase II study. Blood (ASH Annual Meeting Abstracts) 120(21) (#901), 11/2012.
50. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, and Neelapu S. Phase II safety and efficacy study of CT-011, a humanized anti-PD-1 monoclonal antibody, in combination with rituximab in patients with relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#793), 11/2012.
51. Fanale M, Lai C, Rimes S, Ramirez M, Hagemeister F, Fowler N, Younes A, Fayad L, Rodriguez MA, Turturro F, Samaniego F, Romaguera J, Levin V, Horowitz S, Woolery J, and Milbourne A. Positive maternal-fetal outcomes with treatment of lymphoma during pregnancy: UT MD Anderson Cancer Center prospective experience. Blood (ASH Annual Meeting Abstracts) 120(21) (#3670), 11/2012.
52. Oki Y, Westin J, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak L, Romaguera J, Fanale M, Younes A, Rodrigues MA, Orlowski R, Wang M, Ouzounian S, Samaniego F, and Fayad L. R-HCVAD alternating with R-methotrexate cytrabine in younger patients (pts) with IH and high-risk age adjusted-IPI DLBCL. Blood (ASH Annual Meeting Abstracts) 120(21) (#3707), 11/2012.
53. Oki Y, Chuang H, Chasen B, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister FB, Rodriguez A, Neelapu S, Samaniego F, Kwak L, and Younes A. The prognostic value of interim PET scan in patients with classical Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 120(21) (#1529), 11/2012.
54. Nelson K, Samaniego F, Hagemeister F, Lacerte L, Kwak L Neelapu S, Fayad L, LeBlanc D, and Fowler N. Dermatologic side effects of lenalidomide and rituximab in indolent lymphoma. 2012 Pan Pacific Lymphoma Conference, http://www.unmc.edu/cce/panpacific/index.cfm?L1_ID=21&CONREF=21, 7/2012.
55. Gardner K, Dabaja B, Reed V, Kim M, Gambos D, Sorenson E, and Fowler N. Primary intraocular diffuse large B-cell lymphoma: Outcomes following combined modality treatment. 2012 Pan Pacific Lymphoma Conference, http://www.unmc.edu/cce/panpacific/index.cfm?L1_ID=21&CONREF=21, 7/2012.
56. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA) (#237), 2012.
57. de Vos S, Schreeder M, Flinn I, Coutre S, Leonard J, Wagner-Johnston N, Fowler N, Boccia R, Barrientos J, Boyd T, Sharman J, Holes L, Lannutti B, Johnson D, Jahn T, and Miller L. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, Cal-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin's lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts) 118(21) (#2699), 11/2011.
58. Sharman J, de Vos S, Leonard J, Furman R, Coutre S, Flinn I, Schreeda M, Barrientos J, Wagnor-Johnston N, Boyd T, Fowler N, Holes L, Lannutti B, Johnson D, Jahn T, and Langdon M. A phase 1 study of the selective phosphatidylinositol 3-kinase-delta (PI3Ko) inhibitor, CAL-101 (GS-1101), in combination with rituximab and/or bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 118(21) (#1787), 11/2011.
59. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera J, Fanale M, Fayad L, Fowler N, Huen A, Hagemeister F, Rodriguez M, Neelapu S, Samaniego F, Younes A, and Kwak L. Effects of aprepitant on drug metabolism in lymphoma patients receiving multi-day chemotherapy regimen of cyclophosphamide, doxorubicon, vincristine, prednisone, + rituxan (R/CHOP): Randomized, cross-over study. Blood (ASH Annual Meeting Abstracts) 118(21) (#1613), 11/2011.
60. Khouri I, Saliba R, Valverde R, Samuels B, Korblin M, Alousi A, Anderlini P, Bashir Q, de Lima M, Hosing C, Kebriaei P, Nieto Y, Popat U, Qazilbash M, Neelapu S, Fowler N, Samaniego F, Wang L, Champlin R, and Macainlac H. Nonmyeloablative allogenic stem cell transplantation with/without 90yttrium ibritumomab tiexetan (90YIT) is curative for relapsed follicular lymphoma: Median 9 year follow-up results. Blood (ASH Annual Meeting Abstracts) 118(21) (#662), 11/2011.
61. Fowler N, Neelapu S, Fanale M, Rodriguez M, Pro B, Hagemeister F, Younes A, Shah J, Kwak L, Rodriguez D, and McLaughlin P. Phase II study with R-FND followed by 90-Y Ibritumomab tiuxetan radioimmuntherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21) (#99), 11/2011.
62. Fowler N, Munteanu M, Davis G, Brown P, Czuczman M. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21), 11/2011.
63. Fowler N, Kahanic S, Ferero A, Murteanu M, Davis G, Brown P, Van Den Neste E, Offner F, Bron D, and Czuczman M. Results of a phase II study with bendamustine and ofatumumab in untreated indolents B-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 118(21) (#778), 11/2011.
64. Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski R, Wang W, Pro B, Lacerte L, Samaniego f. High Response Rates with Lenalidomide Plus Rituximab for Untreated Indolent B cell non-Hodgkins Lymphom. Ann Oncol 22(Suppl 4), 6/2011.
65. Fowler N, Mclaughlin P, Fisch M, Dakhil S, Bury M, Fayad L, Shah J, Neelapu S, Romaguera J, Rodriguez D, Ayala A, Kwak L. Rituximab plus sargramostim for the treatment of newly diagnosed follicular lymphoma: Final Results of a Phase II study. Ann Oncol 22(Suppl 4), 6/2011.
66. R. Advani, J. P. Sharman, S. M. Smith, D. A. Pollyea, T. E. Boyd, B. W. Grant, K. S. Kolibaba, J. J. Buggy, A. Hamdy, N. H. Fowler. Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase 1 study. Journal of Clinical Oncology 29(15) (#54096), 5/2011.
67. Batty N, Ghonimi E, Feng L, Younes A, Rodriguez A, Wager E, Martinez F, Wang M, McLaughlin P, Fowler N, and Hagemeister F. Blood transfusion and erythropoiesis stimulating agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts) 116(21) (#3357), 11/2010.
68. Okoroji G, Silva L, Saliba R, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, and Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): Allografting vs conventional therapy. Blood (ASH Annual Meeting Abstracts) 116(21) (#3510), 11/2010.
69. Padmanabhan S, Shea T, Vose J, Reeder C, Berdeja J, McDonagh K, Goy A, Kelly K, Zhou X, Liu H, Fingert H, and Fowler N. Phase I study of an investigational aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 116(21) (#2799), 11/2010.
70. Fowler N, Sharman J, Smith S, Boyd T, Grant B, Kolibaba K, Furman R, Buggy J, Loury D, Hamdy A, and Advani R. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a phase I study. Blood (ASH Annual Meeting Abstracts) 116(21) (#964), 11/2010.
71. Burger J, O'Brien S, Fowler N, Advani R, Sharman J, Furman R, Izumi R, Buggy J, Loury D, Hamdy A, Byrd J, and Blum K. Thr Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demostrates promising clinical activity in chronic lymphomcytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase I studies. Blood (ASH Annual Meeting Abstracts) 116(21) (#57), 11/2010.
72. Fowler N, Sharman JS, Smith SS, Pollyea DP, Boyd TB, Grant BG, Kolibaba KK, Buggy JB, Hamdy AH, Advani, RA. A Phase I Trial of Btk inhibitor PCI-32765 in patients with relapsed non-Hodgkin's lymphoma: Evidence of antitumor activity. Haematologica 95(371(Suppl 2)) (#0893), 6/2010.
73. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 28(15s (Suppl)) (#8036), 5/2010.
74. Perini GF, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler NH, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement, clinica presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M.D. Anderson Cancer Center. ASCO Meeting Abstracts 28(15s (Suppl)) (#8072), 5/2010.
75. Advani R, Sharman JP, Smith SM, Pollyea DA, Boyd TE, Grant BW, Kolibaba KS, Buggy JJ, Hamdy A, Fowler NH. Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. ASCO Meeting Abstracts 28(15s (Suppl)) (#8012), 5/2010.
76. Fowler N, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu S, Fayad L, Pro B, Sergent C, White S, and Samaniego F. A biologic combination of lenalidomide and rituximab for front-Line therapy of indolent b-cell non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 114(22):683, 11/2009.
77. Pollyea D, Smith S, Fowler N, Boyd T, Smith A, Sirisawad M, Honigberg L, Hamdy A, and Advani R. A phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory b cell non-Hodgkin lymphoma and use of a novel flourescent probe pharmacodynamic assay. Blood (ASH Annual Meeting Abstracts) 114(22):1430, 11/2009.
78. Westin J, Thompson M, Cataldo V, Toth B, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, and Hagemeister F. Bone loss in lymphoma patients receiving frontline therapy: Urine NTx and bone specific alkaline phosphatase provide early evidence of zoledronic acid response. Blood (ASH Annual Meeting Abstracts) 114(22):1508, 11/2009.
79. Fowler N, Kahl B, Rosen P, Matous J, Cashen A, Jacobs S, Letzer J, Amin B, Williams M, Ross M, Smith S, Saleh A, Shi H, Parasuraman S, and Cheson B. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: Encouraging activity in the phase 2 VERTICAL study. Blood (ASH Annual Meeting Abstracts) 114(22):384, 11/2009.
80. Mazloom A, Fowler N, Iyengar P, and Dabaja B. Primary testicular diffuse large b-cell lymphoma, M.D. Anderson Cancer Center experience. Blood (ASH Annual Meeting Abstracts) 114(22):1055, 11/2009.
81. Vadhan-Raj S, Fayad L, Fanale M, Pro B, Rodriguez A, Hagemeister F, Ames K, Buesno-Ramos C, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, and Romaugera J. Randomized clinical trial of rasburicase administered as a standard fixed five days dosing vs a single dose followed by as needed dosing in adult patients with hematologic malignancies at risk for developing tumor lysis syndrome. Blood (ASH Annual Meeting Abstracts) 114(22):48, 11/2009.
82. Khouri I, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett R, Amin A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak A, Erwin B, Fayad L, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, and Podoloff D. Stem cell transplantation with 90yttrium ibritumomab tiuxetan (90YIT) in non-Hodgkin's lymphoma (NHL): Observations from PET pre-treatment imaging and responses in allografted refractory follicular histologies. Blood (ASH Annual Meeting Abstracts) 114(22):357, 11/2009.
83. Fowler N, Khan S, and Gilliam M. Non-Hodgkin's lymphoma and hepatitis c: prevalence of co-infection and outcomes following anti-viral therapy: a review of the literature. 2009 Pan Pacific Lymphoma Conference, 8/2009.
84. Fowler N, McLaughlin P, Kwak L, Fanale M, Hagemeister F, Fayad L, Pro B, and Samaniego F. Lenolidomide and rituxan for untreated indolent b cell non-Hodgkin's lymphoma. ASCO Meeting Abstracts 27(15s) (#8558), 5/2009.
85. Cataldo V, Thompson M, Toth B, Sanjoro P, Bekele N, Jimenez C, Murphy W, Huen A, Arbuckle R, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, and Hagemeister F. Bone loss in patients with previously untreated lymphoma: The effect of periodontal disease on the use of zoledronic acid. Blood (ASH Annual Meeting Abstracts) 112:5297, 11/2008.
86. McLaughlin P, Neelapu S, Fanale M, Rodriguez M, Ayala A, Pro B, Hagemeister F, Younes A, Neel S, Fowler N, Hess M, and Kwak L. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 112:3056, 11/2008.
87. S.A. Siddique, N. Fowler, E. Asatiani, B. Mavromatis, P. Cohen, C.M. Kessler and B.D. Cheson. Infectious complications associated with alemtuzumab treatment. ASCO Meeting Abstracts 25(18S) (#13504), 6/2007.
88. Westin J, Chu F, Fayad L, Kwak L, Fowler N, Romaguera J, Hagemeister F, Allen R, Feng L, Baladandayuthapani V, Yehudar R, Davis E, Neelapu S. Phase II safety and efficacy study of pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma. Annals of Oncology. Submitted.
89. DeVos S, Wilson W, Gerecitano J, Goy A, Kenkre V, Barr P, Blum K, Shustov A, Advani R, Fowler N, Vose J, Lih C, Williams M, Schmitz R, Yang Y, Pittaluga S, Wright, G, Kunkel L, McGreivy J, Beaurpe D, Balasubramanian S, Cheng M, Moussa D, Chang L, Buggy J, Staudt L. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B-cell-like (ABC) subtype of relapsed/refractory (R/R) DLBCL: Interim. Haematologica. Submitted.
90. Coutre S, Leonard J, Furman R, Flinn I, de Vos S, Rai K, Schreeder M, Wagner-Johnston, Sharman J, Boyd T, Fowler N, Kim Y, Holes L, Johnson D, Dansey R, Jahn T, Barrientos J. Update on a phase I study of the selective P13K-delta inhibitor, idelaslisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic leukemia. Haematologica. Submitted.

Book Chapters

1. Fowler N, McLaughlin P. Non-Hodgkin's Lymphoma. In: Advances in Malignant Hematology. Ed(s) Saba, HI and Mufti, GJ. Wiley-Blackwell: Oxford, UK, 2011.
2. McLaughlin P, Fowler N, Liu N, Medeiros J. The Indolent Lymphomas. In: The MD Anderson Manual of Medical Oncology, 2nd Edition. McGraw-Hill, 2010.
3. Fowler N, Horowitz S, McLaughlin P. Therapy of B-cell lymphoproliferative disorders. In: Experimental and Clinical Hematopathology. Ed(s) D Jones. Springer/Humana, 2010.

Grant & Contract Support

Title: Developing NK-Cell Therapies to Enhance the Treatment of non-Hodgkin Lymphoma
Funding Source: SPORE
Role: Principal Investigator
Duration: 9/1/2010 - 7/31/2011

Last updated: 1/29/2016